Tuberculosis vaccines

British Medical Bulletin

Volumn 62, Issue , 2002, Pages 73-86

  Young, Douglas B ^a   Stewart, Graham R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSFORMING GROWTH FACTOR BETA;

BCG VACCINATION; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LEPROSY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; VACCINATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; BCG VACCINE; CLINICAL TRIALS; HUMANS; IMMUNITY, CELLULAR; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 0036323052     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/62.1.73     Document Type: Review

References (50)

1. Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country
2. The BCG experience: Implications for future vaccines against tuberculosis
3. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis
4. Comparative genomics of BCG vaccines by whole-genome DNA microarray
5. Mouse model of tuberculosis
6. Disease model: Pulmonary tuberculosis
7. Vaccination of cattle against Mycobacterium bovis
8. Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: Implications for primate models in tuberculosis vaccine research
9. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: Meta-analyses of the published literature
10. Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi
11. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis
12. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi
13. Routine vaccinations and child survival: Follow up study in Guinea-Bissau, West Africa
14. Mycobacterium tuberculosis: Here today, and here tomorrow
15. Effects of cytokines on mycobacterial phagosome maturation
16. Immunology of tuberculosis
17. Attenuation of HLA-DR expression by mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature class II heterodimers
18. Failure to induce enhanced protection against tuberculosis by increasing T-cell-dependent interferon-gamma generation
19. How can immunology contribute to the control of tuberculosis?
20. Tuberculosis vaccine development: Recent progress
21. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculosis lesions
22. Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection
23. Auxotrophic vaccines for tuberculosis
24. Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin
25. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines
26. Enhanced antimycobacterial response to recombinant Mycobacterium bovis BCG expressing latency-associated peptide
27. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model
28. Overexpression of heat-shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection
29. Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes
30. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates
31. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis
32. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice
33. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis
34. An essential role for phoP in Mycobacterium tuberculosis virulence
35. TB vaccines: Progress and problems
36. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis
37. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection
38. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis
39. Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells
40. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6
41. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine
42. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis
43. Enhanced immunogenicity of CD4(+) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis
44. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen
45. Therapy of tuberculosis in mice by DNA vaccination
46. Simple, practical ways to assess the protective efficacy of a new tuberculosis vaccine
47. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: A randomised controlled trial